# Praxis Precision Medicines Posts Q3 GAAP Net Loss of $3.23 Per Share

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52896
Published: 2026-11-10T07:40:07.000Z
Updated: 2026-11-10T07:40:07.000Z
Section: Business

> Cash, cash equivalents and marketable securities totaled $1.3 billion on Sept. 30, compared with $926.1 million on Dec. 31, 2025.

Praxis Precision Medicines posted a GAAP net loss of $3.23 per basic and diluted share for the third quarter of 2026, while its cash, cash equivalents and marketable securities totaled $1.3 billion at quarter-end.

The company held $926.1 million in those assets on Dec. 31, 2025.